China's Chemical API Industry Accelerates Structural Upgrading Amid Global Realignment

As the global chemical active pharmaceutical ingredient (API) industry undergoes structural realignment, China has consolidated its position as the world's largest producer and exporter of APIs. In addition to meeting domestic demand from formulation manufacturers, many Chinese APIs have demonstrated strong international competitiveness. After decades of development, the chemical API sector — one of the strategic pillars of China's pharmaceutical industry — has formed a relatively complete industrial system, characterised by large-scale production, cost advantages, and high output capacity.

Industry Scale and Market Position Continue to Strengthen

In 2024, chemical API enterprises above designated size in China generated revenues of RMB 578.3 billion, accounting for 35.5% of the global API market and 22.9% of total revenues among China's pharmaceutical enterprises above designated size. Revenue increased by 4.2% year-on-year, while market share rose by 0.9 percentage points. Compared with 2014, industry revenue expanded by 36.4%, and its share increased by 5.4 percentage points, underscoring China's growing global influence.

The sector experienced a minor revenue peak in 2016, followed by a gradual downturn through 2019, when revenues declined to RMB 380.4 billion and market share fell to a historical low of 14.5%. Since 2020, both revenue and market share have rebounded annually, reaching record highs in 2024. This recovery was driven by two key factors: first, pandemic-related production disruptions in major global API hubs such as India, Italy, and Spain, which prompted Chinese exports to fill supply gaps; second, China's centralised procurement policy, which encouraged chemical drug manufacturers to trade volume for price, triggering a surge in API demand.

Competitive Landscape: Leaders Advance, SMEs Under Pressure

China dominates traditional API segments including antibiotics, vitamins, and antipyretic analgesics, while steadily expanding into higher-end fields such as specialty APIs and biopharmaceutical APIs. However, the industry faces mounting challenges, including stricter environmental regulations, escalating international trade frictions, and intensified homogeneous competition.

The current market structure exhibits a clear 'leader-driven, SME-strained' pattern. Leading enterprises with technological advantages and integrated supply chains have achieved both volume and price growth in cyclical products such as vitamins and amino acids. Through horizontal expansion and effective cost control, their performance has significantly outpaced industry averages. In contrast, many companies focused on traditional anti-infective APIs face declining revenues and margins due to global overcapacity, prolonged price downturns, and intensifying international competition. Emerging markets, particularly India, continue to erode China's traditional export share through lower production costs, while localisation policies in developed economies further constrain overseas market access.

Technological Innovation Becomes the Core Breakthrough

Amid cyclical volatility and fierce competition, technological innovation has become central to overcoming structural bottlenecks. Traditional chemical synthesis processes are gradually transitioning toward greener and smarter production methods. Technologies such as continuous flow reactions and biocatalysis have improved production efficiency and product purity while reducing energy consumption and environmental costs. The large-scale application of biosynthetic technologies in products such as steroid hormones and amino acids has not only addressed limitations inherent in chemical synthesis but also opened new pathways for higher value-added production.

At the same time, collaboration across the industrial chain and business model innovation are accelerating sector restructuring. The 'API + CDMO' model has emerged as a key transformation route for small and medium-sized enterprises, shifting from single-product manufacturing toward technical services and customised production for innovative pharmaceutical companies. Leading enterprises are also diversifying their business structures by integrating segments such as nutritional supplements, APIs, and polymer materials to mitigate cyclical risks and enhance operational resilience. Meanwhile, intelligent manufacturing and digital management are driving a transition from experience-based to data-driven production, significantly improving quality control and supply chain responsiveness.

Policy Support and Long-Term Outlook

Despite progress in innovation and model upgrading, structural contradictions within the pharmaceutical industry remain unresolved. Price volatility, external market uncertainties, and policy adjustments continue to challenge enterprises as they balance short-term profitability with long-term strategy. Over the next five years, the industry will operate in an increasingly complex environment. On the demand side, global pharmaceutical market growth, China's rapidly ageing population, and rising chronic disease prevalence will underpin expansion. Conversely, international trade barriers, rising environmental compliance costs, and technological substitution risks are expected to further compress margins.

Against this backdrop, competition is shifting from cost-based rivalry toward comprehensive competition encompassing technology, quality, and supply chain resilience. Enterprises with proprietary technologies, stable capacity, and international operational capabilities are expected to emerge as industry leaders.

In early January this year, policy documents issued by the General Office of the State Council called for cultivating a globally competitive innovation ecosystem to support China's transition from a major pharmaceutical producer to a pharmaceutical powerhouse, better meeting public demand for high-quality medicines and medical devices. Chemical APIs are positioned to play a pivotal role in this strategic transformation.

Currently, China's API industry stands at a critical juncture marked by cyclical fluctuations and structural opportunities. Over the next five years, development is expected to follow a trajectory of 'overall growth with structural optimisation',   with traditional bulk APIs increasingly concentrated among leading firms, while specialty and biopharmaceutical APIs become new growth drivers. Green manufacturing and intelligent technologies will underpin the industry's shift toward high-quality development.

In the long term, China's global competitiveness in APIs will depend not only on cost advantages but, more importantly, on technological innovation and supply chain resilience. As domestic enterprises achieve breakthroughs in high-end products and deepen their international presence, the sector is poised to evolve from the 'world's factory' into an 'innovation leader',   providing critical support for global pharmaceutical supply chain stability and the advancement of the Healthy China initiative.